Skip to main content

LGC Biosearch Technologies Gets FDA Emergency Use Authorization for SARS-CoV-2 Test

This article has been updated from a previous version to clarify language about the March 2020 authorization granted to kits supplied by LGC Biosearch.

NEW YORK — The US Food and Drug Administration on Thursday granted Emergency Use Authorization for a PCR-based SARS-CoV-2 test developed by LGC Biosearch Technologies, a Petaluma, California-based division of UK-headquartered LGC.

The Biosearch Technologies SARS-CoV-2 Real-Time and End-Point RT-PCR Test is designed to detect the N gene of the virus in samples collected by a healthcare provider, including anterior nasal, midturbinate nasal, nasopharyngeal, or oropharyngeal swabs, as well as nasopharyngeal washes/aspirates or nasal aspirates. It runs on LGC Biosearch's IntelliQube qPCR instrument.

The test may be used by any lab CLIA-certified to perform high-complexity tests, according to the FDA.

In March 2020, LGC Biosearch Technologies noted that it was supplying Emergency Use Authorized SARS-CoV-2 testing kits developed by the US Centers for Disease Control and Prevention.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.